Literature DB >> 23027934

Neuroprotective efficacy of aminopropyl carbazoles in a mouse model of Parkinson disease.

Héctor De Jesús-Cortés1, Pin Xu, Jordan Drawbridge, Sandi Jo Estill, Paula Huntington, Stephanie Tran, Jeremiah Britt, Rachel Tesla, Lorraine Morlock, Jacinth Naidoo, Lisa M Melito, Gelin Wang, Noelle S Williams, Joseph M Ready, Steven L McKnight, Andrew A Pieper.   

Abstract

We previously reported the discovery of P7C3, an aminopropyl carbazole having proneurogenic and neuroprotective properties in newborn neural precursor cells of the dentate gyrus. Here, we provide evidence that P7C3 also protects mature neurons in brain regions outside of the hippocampus. P7C3 blocks 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-mediated cell death of dopaminergic neurons in the substantia nigra of adult mice, a model of Parkinson disease (PD). Dose-response studies show that the P7C3 analog P7C3A20 blocks cell death with even greater potency and efficacy, which parallels the relative potency and efficacy of these agents in blocking apoptosis of newborn neural precursor cells of the dentate gyrus. P7C3 and P7C3A20 display similar relative effects in blocking 1-methyl-4-phenylpyridinium (MPP(+))-mediated death of dopaminergic neurons in Caenorhabditis elegans, as well as in preserving C. elegans mobility following MPP(+) exposure. Dimebon, an antihistaminergic drug that is weakly proneurogenic and neuroprotective in the dentate gyrus, confers no protection in either the mouse or the worm models of PD. We further demonstrate that the hippocampal proneurogenic efficacy of eight additional analogs of P7C3 correlates with their protective efficacy in MPTP-mediated neurotoxicity. In vivo screening of P7C3 analogs for proneurogenic efficacy in the hippocampus may thus provide a reliable means of predicting neuroprotective efficacy. We propose that the chemical scaffold represented by P7C3 and P7C3A20 provides a basis for optimizing and advancing pharmacologic agents for the treatment of patients with PD.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23027934      PMCID: PMC3479520          DOI: 10.1073/pnas.1213956109

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  22 in total

1.  In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining.

Authors:  N A Tatton; S J Kish
Journal:  Neuroscience       Date:  1997-04       Impact factor: 3.590

2.  Selectivity of the parkinsonian neurotoxin MPTP: toxic metabolite MPP+ binds to neuromelanin.

Authors:  R J D'Amato; Z P Lipman; S H Snyder
Journal:  Science       Date:  1986-02-28       Impact factor: 47.728

3.  Antihistamine agent Dimebon as a novel neuroprotector and a cognition enhancer.

Authors:  S Bachurin; E Bukatina; N Lermontova; S Tkachenko; A Afanasiev; V Grigoriev; I Grigorieva; Y Ivanov; S Sablin; N Zefirov
Journal:  Ann N Y Acad Sci       Date:  2001-06       Impact factor: 5.691

4.  Analysis of the constancy of DNA sequences during development and evolution of the nematode Caenorhabditis elegans.

Authors:  S W Emmons; M R Klass; D Hirsh
Journal:  Proc Natl Acad Sci U S A       Date:  1979-03       Impact factor: 11.205

5.  Neurotoxin-induced degeneration of dopamine neurons in Caenorhabditis elegans.

Authors:  Richard Nass; David H Hall; David M Miller; Randy D Blakely
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-26       Impact factor: 11.205

Review 6.  Neurotoxicity of MPTP.

Authors:  T Fukuda
Journal:  Neuropathology       Date:  2001-12       Impact factor: 1.906

7.  Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation.

Authors:  M E Gurney; H Pu; A Y Chiu; M C Dal Canto; C Y Polchow; D D Alexander; J Caliendo; A Hentati; Y W Kwon; H X Deng
Journal:  Science       Date:  1994-06-17       Impact factor: 47.728

Review 8.  Human beta-secretase (BACE) and BACE inhibitors.

Authors:  Varghese John; James P Beck; Michael J Bienkowski; Sukanto Sinha; Robert L Heinrikson
Journal:  J Med Chem       Date:  2003-10-23       Impact factor: 7.446

9.  Mitochondria as a target for neurotoxins and neuroprotective agents.

Authors:  Sergey O Bachurin; Elena P Shevtsova; Elena G Kireeva; Gregory F Oxenkrug; Sergey O Sablin
Journal:  Ann N Y Acad Sci       Date:  2003-05       Impact factor: 5.691

10.  Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity.

Authors:  J A Javitch; R J D'Amato; S M Strittmatter; S H Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  1985-04       Impact factor: 11.205

View more
  60 in total

Review 1.  Pyridine Dinucleotides from Molecules to Man.

Authors:  Joshua P Fessel; William M Oldham
Journal:  Antioxid Redox Signal       Date:  2017-07-25       Impact factor: 8.401

Review 2.  Pharmacological inhibition of Bax-induced cell death: Bax-inhibiting peptides and small compounds inhibiting Bax.

Authors:  Kelsey Jensen; David Jasen WuWong; Sean Wong; Mieko Matsuyama; Shigemi Matsuyama
Journal:  Exp Biol Med (Maywood)       Date:  2019-03-05

3.  Protective effect of P7C3 on retinal ganglion cells from optic nerve injury.

Authors:  Hidehiro Oku; Seita Morishita; Taeko Horie; Yuko Nishikawa; Teruyo Kida; Masashi Mimura; Shota Kojima; Tsunehiko Ikeda
Journal:  Jpn J Ophthalmol       Date:  2016-12-28       Impact factor: 2.447

Review 4.  Neurotherapeutic capacity of P7C3 agents for the treatment of Traumatic Brain Injury.

Authors:  Meghan O Blaya; Joseph M Wasserman; Andrew A Pieper; Thomas J Sick; Helen M Bramlett; W Dalton Dietrich
Journal:  Neuropharmacology       Date:  2018-09-17       Impact factor: 5.250

5.  Neurodegenerative diseases: Novel route to neuroprotection.

Authors:  Samia Burridge
Journal:  Nat Rev Drug Discov       Date:  2012-12       Impact factor: 84.694

6.  The P7C3 class of neuroprotective compounds exerts antidepressant efficacy in mice by increasing hippocampal neurogenesis.

Authors:  A K Walker; P D Rivera; Q Wang; J-C Chuang; S Tran; S Osborne-Lawrence; S J Estill; R Starwalt; P Huntington; L Morlock; J Naidoo; N S Williams; J M Ready; A J Eisch; A A Pieper; J M Zigman
Journal:  Mol Psychiatry       Date:  2014-04-22       Impact factor: 15.992

7.  High-Content Microfluidic Screening Platform Used To Identify σ2R/Tmem97 Binding Ligands that Reduce Age-Dependent Neurodegeneration in C. elegans SC_APP Model.

Authors:  Sudip Mondal; Evan Hegarty; James J Sahn; Luisa L Scott; Sertan Kutal Gökçe; Chris Martin; Navid Ghorashian; Praveen Navoda Satarasinghe; Sangeetha Iyer; Wisath Sae-Lee; Timothy R Hodges; Jonathan T Pierce; Stephen F Martin; Adela Ben-Yakar
Journal:  ACS Chem Neurosci       Date:  2018-02-23       Impact factor: 4.418

8.  Neuroprotection of MAO-B inhibitor and dopamine agonist in Parkinson disease.

Authors:  Ping Kong; Benshu Zhang; Ping Lei; Xiaodong Kong; Shishuang Zhang; Dai Li; Yun Zhang
Journal:  Int J Clin Exp Med       Date:  2015-01-15

9.  Beneficial Effects of Delayed P7C3-A20 Treatment After Transient MCAO in Rats.

Authors:  Zachary B Loris; Justin R Hynton; Andrew A Pieper; W Dalton Dietrich
Journal:  Transl Stroke Res       Date:  2017-08-25       Impact factor: 6.829

Review 10.  Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence.

Authors:  Luis Rajman; Karolina Chwalek; David A Sinclair
Journal:  Cell Metab       Date:  2018-03-06       Impact factor: 27.287

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.